美国173家医院革兰阴性菌血流感染中难治性耐药:全一线药物耐药的患病率、预测因素与结局的回顾性队列分析
基于Premier数据库2009至2013年173家医院45011例革兰阴性菌血流感染住院患者,难治性耐药(DTR)定义为对所有β-内酰胺类(含碳青霉烯类)和氟喹诺酮类体外中介或耐药。DTR发生471例(1%),不同菌种从大肠埃希菌0.04%至鲍曼不动杆菌18.4%不等;DTR患者粗死亡率43%,校正后死亡相对风险高于碳青霉烯类耐药、超广谱头孢菌素耐药和氟喹诺酮类耐药表型。
要点
- DTR定义为对所有β-内酰胺类(含碳青霉烯类)和氟喹诺酮类体外中介或耐药。
- DTR发生率为1%(471/45011),大肠埃希菌0.04%,鲍曼不动杆菌18.4%。
- DTR患者粗死亡率43%,校正后死亡风险高于其他耐药表型。
核心结论
- 对一线抗生素不耐药与革兰阴性菌血流感染生存率下降相关;DTR是简便的床旁预后指标,反映限制治疗的核心耐药。
研究设计与样本
- 回顾性队列分析,基于Premier数据库2009至2013年173家医院45011例革兰阴性菌血流感染住院患者,其中92家医院(53.2%)出现DTR病例。
主要发现
- DTR发生471例(1%),范围从大肠埃希菌0.04%至鲍曼不动杆菌18.4%。
- DTR患者中79%接受肠外氨基糖苷类、替加环素或多黏菌素/多黏菌素B治疗,33%对所有氨基糖苷类耐药。
- DTR预测因素包括城市医疗环境和较高基线疾病严重程度。
- DTR患者粗死亡率43%;校正后死亡相对风险高于碳青霉烯类耐药(aRR 1.2;95%CI 1.0-1.4;P=.02)、超广谱头孢菌素耐药(aRR 1.2;95%CI 1.1-1.4;P=.001)和氟喹诺酮类耐药(aRR 1.2;95%CI 1.0-1.4;P=.008)感染。
- 有效一线药物类别从3-5类降至1-2类再降至0类,死亡校正相对风险每级增加20%。
关键数值与推荐
- DTR定义为对所有β-内酰胺类(含碳青霉烯类)和氟喹诺酮类体外中介或耐药。
- 采用CDC定义比较DTR与碳青霉烯类耐药、超广谱头孢菌素耐药和氟喹诺酮类耐药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Resistance to all first-line antibiotics necessitates the use of less effective or more toxic "reserve" agents. Gram-negative bloodstream infections (GNBSIs) harboring such difficult-to-treat resistance (DTR) may have higher mortality than phenotypes that allow for ≥1 active first-line antibiotic. METHODS: The Premier Database was analyzed for inpatients with select GNBSIs. DTR was defined as intermediate/resistant in vitro to all ß-lactam categories, including carbapenems and fluoroquinolones. Prevalence and aminoglycoside resistance of DTR episodes were compared with carbapenem-resistant, extended-spectrum cephalosporin-resistant, and fluoroquinolone-resistant episodes using CDC definitions. Predictors of DTR were identified. The adjusted relative risk (aRR) of mortality was examined for DTR, CDC-defined phenotypes susceptible to ≥1 first-line agent, and graded loss of active categories. RESULTS: Between 2009-2013, 471 (1%) of 45011 GNBSI episodes at 92 (53.2%) of 173 hospitals exhibited DTR, ranging from 0.04% for Escherichia coli to 18.4% for Acinetobacter baumannii. Among patients with DTR, 79% received parenteral aminoglycosides, tigecycline, or colistin/polymyxin-B; resistance to all aminoglycosides occurred in 33%. Predictors of DTR included urban healthcare and higher baseline illness. Crude mortality for GNBSIs with DTR was 43%; aRR was higher for DTR than for carbapenem-resistant (1.2; 95% confidence interval, 1.0-1.4; P = .02), extended-spectrum cephalosporin-resistant (1.2; 1.1-1.4; P = .001), or fluoroquinolone-resistant (1.2; 1.0-1.4; P = .008) infections. The mortality aRR increased 20% per graded loss of active first-line categories, from 3-5 to 1-2 to 0. CONCLUSION: Nonsusceptibility to first-line antibiotics is associated with decreased survival in GNBSIs. DTR is a simple bedside prognostic measure of treatment-limiting coresistance.
引用
- Kadri SS, Adjemian J, Lai YL, et al. Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. Clin Infect Dis. 2018. PMID: 30052813. doi:10.1093/cid/ciy378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。